Back to Browse Journals » International Journal of High Throughput Screening » Volume 1

Development of a functional HTS assay for the APJ receptor

Authors Angela Giddings, Scott Runyon, James Thomas, et al

Published Date April 2010 Volume 2010:1 Pages 39—47


Published 19 April 2010

Angela Giddings1, Scott Runyon2, James Thomas2, Julianne Tajuba1, Katherine Bortoff1, Rangan Maitra1

1Center for Pharmacology and Toxicology, 2Center for Organic and Medicinal Chemistry, Division of Discovery Sciences, RTI International, Research Triangle Park, NC, USA

Abstract: The apelin receptor (APJ) is rapidly emerging as an attractive therapeutic target for various diseases. To date, only one nonpeptide APJ agonist has been reported and new chemotypes having improved pharmacological properties are needed to expedite maturation of this receptor as a viable target. Therefore, the development of a high-throughput screening (HTS) assay for APJ should facilitate the discovery of novel ligands as in vivo probes of APJ function. In this report, an HTS compatible assay for the APJ is demonstrated. This assay takes advantage of functional coupling of APJ with the promiscuous Gαq16 protein and consequent mobilization of intracellular calcium, which can be measured in a microplate format using a fluorescent calcium probe. The assay was developed and validated using several known peptides derived from preproapelin. Most of the apelin peptides tested activated APJ at subnanomolar concentrations in accordance with their reported median effective concentration values. The assay was deemed robust and reproducible with a Z-factor of ∼0.6 and tolerance to ethanol, dimethyl sulfoxide or a mixture of these two commonly used solvents to a final concentration of 1%. The assay was further validated by screening a small library of compounds for APJ activity. A hit rate of ∼0.5% was achieved and confirmed by counter-screening against parental Gαq16 cells lacking APJ. In conclusion, an HTS assay has been established to rapidly identify new ligands for the APJ. Novel APJ ligands having suitable drug-like properties are greatly needed to probe the in vivo pharmacology of this emerging therapeutic target.
Keywords: APJ, apelin, Gαq16, GPCR, HTS, assay

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012

Impact of interleukin-27 on replication of hepatitis C virus

Scotto G, Giammario A, Campanale F, D’Addiego G, Fazio V

International Journal of Interferon, Cytokine and Mediator Research 2011, 3:79-89

Published Date: 22 December 2011

Epigenomics in cancer management

Fabricio F Costa

Cancer Management and Research 2010, 2:255-265

Published Date: 27 October 2010

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab

Naveed Wagle, Leia Nghiemphu, Albert Lai, et al

Pharmacogenomics and Personalized Medicine 2010, 3:79-85

Published Date: 9 June 2010

Role of human beta defensin 3 during type I interferon mediated antiviral response against vesicular stomatitis virus

Mausumi Basu, Srikanth Kota, Amiya K Banerjee, et al

International Journal of Interferon, Cytokine and Mediator Research 2010, 2:23-32

Published Date: 3 March 2010

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009